key: cord-0684924-x7cq2hu0 authors: Lindsley, Andrew W.; Schwartz, Justin T.; Rothenberg, Marc E. title: Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination date: 2020-04-25 journal: J Allergy Clin Immunol DOI: 10.1016/j.jaci.2020.04.021 sha: ec85e354a9dde1350c59fb5cd9e7338d7eb023ec doc_id: 684924 cord_uid: x7cq2hu0 Abstract Eosinophils are circulating and tissue-resident leukocytes that have potent pro-inflammatory effects in a number of diseases. Recently, eosinophils have been shown to have a variety of other functions, including immunoregulation and antiviral activity. Eosinophil levels vary dramatically in a number of clinical settings, especially following eosinophil-targeted therapy, which is now available to selectively deplete these cells. There are key COVID-19–related questions concerning eosinophils whose answers affect recommended prevention and care. First, do patients with eosinophilia-associated diseases have an altered course of COVID-19? Second, do patients with eosinopenia (now intentionally induced by biological drugs) have unique COVID-19 susceptibility and/or disease course? This is a particularly relevant question as eosinopenia is associated with acute respiratory deterioration during infection with the Severe Acute Respiratory Syndrome (SARS)-Corona Virus (CoV)-2, the causative agent of COVID-19. Third, do eosinophils contribute to the lung pathology induced during COVID-19 and will they contribute to immunopotentiation potentially associated with emerging COVID-19 vaccines? Herein, we address these timely questions and project considerations during the emerging COVID-19 pandemic. effects in a number of diseases. Recently, eosinophils have been shown to have a variety of other 48 functions, including immunoregulation and antiviral activity. Eosinophil levels vary dramatically 49 in a number of clinical settings, especially following eosinophil-targeted therapy, which is now 50 available to selectively deplete these cells. There are key COVID-19-related questions 51 concerning eosinophils whose answers affect recommended prevention and care. First, do 52 patients with eosinophilia-associated diseases have an altered course of COVID-19? Second, do 53 patients with eosinopenia (now intentionally induced by biological drugs) have unique COVID-54 19 susceptibility and/or disease course? This is a particularly relevant question as eosinopenia is 55 associated with acute respiratory deterioration during infection with the Severe Acute 56 Respiratory Syndrome (SARS)-Corona Virus (CoV)-2, the causative agent of 57 do eosinophils contribute to the lung pathology induced during COVID-19 and will they 58 contribute to immunopotentiation potentially associated with emerging COVID-19 vaccines? 59 Herein, we address these timely questions and project considerations during the emerging 60 COVID-19 pandemic. 61 62 Eosinophils normally account for only a small percentage of circulating leukocytes (1-3%), but 64 their levels can vary in a variety of disease states. 1-3 Their level is clinically relevant as 65 eosinophils are potent pro-inflammatory cells, primarily due to their pre-formed granules, which 66 are packed with cytotoxic proteins, including major basic protein (one of the most basically 67 charged molecules in the body), eosinophil peroxidase, and two RNAses (eosinophil cationic 68 protein and eosinophil neurotoxin). In addition to their pro-inflammatory effects, evidence is 69 emerging, albeit primarily in mice, that eosinophils have pleotropic roles as regulatory cells There are a number of diseases associated with eosinophil expansion in which eosinophils are 78 causally related to the disease pathology, such as subsets of moderate and severe asthma. 79 Accordingly, a number of clinically approved biological antibody-based precision therapies are 80 now available that directly target eosinophils, resulting in eosinophil depletion. 5 These drugs 81 include those that neutralize the eosinophil growth and activating factor interleukin 5 (IL-5) (e.g., 82 mepolizumab and reslizumab) and drugs that directly induce eosinophil depletion by antibody-83 dependent cellular cytotoxicity (e.g., the anti-IL-5 receptor drug benralizumab). 6 These drugs 84 have remarkable beneficial effects in a growing number of diseases, including asthma, 85 hypereosinophilic syndrome, and eosinophilic granulomatous polyangiitis (formerly known as 86 Churg Strauss syndrome), and additional clinical indications are actively being pursued. As a 87 result, there is now an increasing number of patients with biological drug-induced eosinopenia. 7 88 Though patients with abnormally low eosinophil levels (referred to as eosinopenia) might be 89 considered at risk for diseases normally controlled by eosinophils, there have been no major side 90 effects associated with these therapies to date. In addition to biological drug-induced 91 eosinopenia, eosinophil depletion occurs in response to multiple triggers of acute inflammation, 8 92 including during sepsis, and multiple studies have consistently shown that low eosinophil levels 93 correlate with poor outcome in critically ill patients. 9 94 There are now key COVID-19-related questions concerning eosinophils whose answers affect 96 recommended prevention and care. First, do patients with eosinophilia-associated diseases have 97 an altered course of COVID-19? Second, do patients with eosinopenia have unique COVID-19 98 disease features? This is a particularly relevant question as eosinopenia has already been reported 99 in patients with acute respiratory deterioration during infection with the Severe Acute 100 Respiratory Syndrome (SARS)-Corona Virus (CoV)-2, the causative agents of COVID-19. 10 101 Third, do eosinophils contribute to the lung pathology induced during COVID-19 and will they 102 contribute to adverse events associated with emerging COVID-19 vaccines? Indeed, eosinophil-103 associated lung pathology is known to occur following certain viral infections (e.g., respiratory 104 syncytial virus [RSV] ) and importantly is a known complication in prior SARS-CoV-1 105 vaccination studies (see Table 1 ). On the basis of prior experience with SARS-CoV vaccines, it 106 is expected that COVID-19 vaccines will need careful safety evaluations for immunopotentiation 107 that might increase infectivity and/or eosinophilic infiltration. 11 108 109 110 The role of eosinophils in mucosal immune responses in the respiratory tract has largely focused 112 on the detrimental impact that these cells can have in inflammatory responses due to their potent 113 pro-inflammatory function. On the other hand, preclinical studies (mainly in mice) have shown 114 that eosinophils are equipped with an assortment of molecular tools that enable them to 115 recognize, respond, and orchestrate antiviral responses to respiratory viruses. 12 Human 116 eosinophils express several endosomal toll-like receptors (TLRs), including TLR3, TLR7 and 117 TLR9, that detect viral microbe-associated molecular patterns. 13-15 TLR7 enables eosinophils to 118 recognize single-stranded RNA (ssRNA) viruses like coronavirus, and stimulating this receptor 119 in human eosinophils triggers eosinophil cytokine production, degranulation, superoxide and 120 nitric oxide (NO) generation, and prolonged cellular survival. 14-16 Eosinophil-derived neurotoxin 121 (EDN/RNAse2) and eosinophil cationic protein (ECP/RNAse3) from human eosinophils reduce 122 infectivity of respiratory syncytial virus (RSV) by a ribonuclease-dependent mechanism. 17, 18 123 Both human and murine eosinophils produce NO via inducible NO synthase that can have direct 124 antiviral effects on parainfluenza virus (PIV) and RSV. 16, 19, 20 Eosinophils are able to produce Although these data substantiate the antiviral potential of eosinophils, the clinical significance of 146 eosinophils in antiviral responses in human disease continues to remain debatable. Patients with 147 eosinophilic asthma have an increased risk for viral-induced asthma exacerbations, and there is 148 mounting evidence that patients with eosinophilic asthma may actually have reduced innate 149 responses against respiratory viruses. 28-30 Importantly, biologic agents that decrease pulmonary 150 eosinophil levels reduce asthma exacerbations, and patients with asthma treated with these 151 agents have not been reported to have increased viral infections. 29, 31-36 Rosenberg et al. 152 suggested that eosinophils in the respiratory tract might represent a "double-edged sword", 153 promoting antiviral responses against some respiratory viruses that could become dysregulated 154 during allergic disease given their increased numbers and/or activation status, ultimately 155 resulting in an exaggerated host response that can lead to host tissue damage. 37 The growing 156 number of biologic agents that target eosinophils may be useful tools to help clarify the role 157 Conversely, multiple studies have identified older age, male sex, hypertension, coronary heart 193 disease, and diabetes as being consistent risk factors for severe COVID-19 disease. 10, 43, 47-49 194 The mechanisms for the male predominance of COVID-19 severity are not known, but it is 195 notable that allergic lung responses to RSV have increased severity in male mice by a TSLP-196 dependent mechanism, and eosinophil associated diseases such as eosinophilic esophagitis and 197 In the decade following these early observations, a series of mouse studies (see Table 1 There are emerging eosinophil-related considerations concerning COVID-19 (Table 2 ). Although 261 current data are limited, there is little supportive evidence that patients with eosinophil-262 associated diseases will have an altered course of COVID-19, provided that they are not 263 immunosuppressed from concurrent medications or by their primary disease process. Likewise, 264 though preclinical studies have provided compelling experimental evidence that eosinophils have 265 potential antiviral activity, there is no evidence that patients with eosinopenia induced by the 266 recently approved anti-eosinophil therapeutics have increased susceptibility to viruses. Whether 267 the acquired eosinopenia associated with COVID-19 is directly contributing to the disease course 268 has not yet been determined, but it is notable that pulmonary eosinophilia is not part of the lung 269 pathology so far attributed to SARS-CoV-2. It will be important however to assess the presence 270 of eosinophils and the deposition of their granule products in the lung of a large cohort of 271 COVID-19 patients, and to control for exposure to glucocorticoids, in order to determine the role 272 of eosinophils in the COVID-19 lung pathology. Finally, and likely most importantly, there is 273 considerable concern about whether SARS-CoV-2 exposure post-vaccination would cause 274 eosinophil-associated lung pathology through immunopotentiation (see Figure 1 ). Though these 275 concerns mainly have been derived from murine studies using vaccine candidates from the 276 original SARS-CoV-1 virus, similar responses have also been seen in other species (e.g., ferrets 277 and monkey studies); it is also notable that SARS-CoV-1 and SARS-CoV-2 share > 80% The antiviral activity of eosinophils is unlikely involved in COVID-19 because the antiviral activity of eosinophils has not yet been observed in humans. There are no data to date substantiating any risk for infections following depletion of eosinophils. The eosinopenia associated with COVID-19 is likely a secondary phenomenon and not directly contributing to the disease course. Vaccine candidates must demonstrate the absence of eosinophil-associated disease enhancement prior to widespread deployment. 295 296 The structural proteins of the SARS-CoV viral particle are shown and putative Th1-vs Th2-298 mediated immune responses detailed. The Spike (S) glycoprotein mediates binding of the virus 299 to the angiotensin-converting enzyme-2 (ACE2) protein and subsequent fusion/entry into host 300 cells. Sera from convalescing patients have revealed that anti-N protein and anti-S protein 301 antibodies predominate the humoral immune response to SARS-CoV-1 but that only anti-S 302 protein antibodies (especially those targeting the receptor binding domain [RBD] region) are 303 neutralizing and protective. Beneficial anti-viral responses appear to be linked to Th1-skewed 304 immunity, whereas Th2 immunopotentiation in multiple animal model systems is associated with 305 vaccination-enhanced disease, leading to pulmonary eosinophilia. To date, these potentially 306 adverse consequences have been observed only in animal model systems following virus 307 challenge with certain vaccine formulations (see Table 1 ). A variety of SARS-CoV-2 vaccine 308 candidates are currently under development (see box), which should be scrutinized for safety 309 prior to widespread deployment. ssRNA, single-stranded RNA. CTL, cytotoxic T lymphocyte. 310 311 312 313 Pediatric 317 Hypereosinophilia: Characteristics, Clinical Manifestations, and Diagnoses An Approach to the Evaluation of Persistent 320 Hypereosinophilia in Pediatric Patients Functions of tissue-resident eosinophils Anti-IL-5 treatments in 324 patients with severe asthma by blood eosinophil thresholds: Indirect treatment 325 comparison Changing 327 Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies Biologics in chronic rhinosinusitis with nasal polyposis Behavior of eosinophil leukocytes in acute inflammation. II. Eosinophil 332 dynamics during acute inflammation White blood cell count and eosinopenia as valuable tools for the diagnosis of bacterial 335 infections in the ED Clinical characteristics of 140 337 patients infected with SARS-CoV-2 in Wuhan The SARS-CoV-2 Vaccine Pipeline: an 339 Overview Eosinophils and 341 Respiratory Viruses TLR3 in 343 human eosinophils: functional effects and decreased expression during allergic rhinitis Expression and function of Toll-like receptors in eosinophils: activation by Toll-like 347 receptor 7 ligand Intracellular signaling mechanisms regulating toll-349 like receptor-mediated activation of eosinophils Eosinophils Have Antiviral Activity against Parainfluenza Virus Eosinophil cationic 355 protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity Recombinant human eosinophil-358 derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory 359 syncytial virus Eosinophils contribute to innate antiviral immunity and promote clearance of 362 respiratory syncytial virus Dual 364 proinflammatory and antiviral properties of pulmonary eosinophils in respiratory 365 syncytial virus vaccine-enhanced disease Respiratory 367 syncytial virus increases eosinophil extracellular traps in a murine model of asthma Oxidative 370 damage of SP-D abolishes control of eosinophil extracellular DNA trap formation Eosinophil cytokines, chemokines, and growth factors: emerging roles 373 in immunity Eosinophils Promote Antiviral Immunity in Mice Infected with Influenza A Virus Eosinophil 378 as antigen-presenting cell: activation of T cell clones and T cell hybridoma by eosinophils 379 after antigen processing Eosinophils bind 381 rhinovirus and activate virus-specific T cells Anti-383 IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage A Placebo-controlled, Double-Blind Study High fractional 387 exhaled nitric oxide and sputum eosinophils are associated with an increased risk of 388 future virus-induced exacerbations: A prospective cohort study Viral infections 391 in allergy and immunology: How allergic inflammation influences viral infections and 392 illness Risks for infection in patients with asthma (or other atopic conditions): is 394 asthma more than a chronic airway disease? Efficacy and 397 safety of benralizumab for patients with severe asthma uncontrolled with high-dosage 398 inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, 399 multicentre Long-401 term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 402 1-year results from the BORA phase 3 extension trial 404 an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for 405 patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, 406 double-blind, placebo-controlled phase 3 trial Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab Long-term Efficacy 411 and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center Open-label, Phase IIIb Study ESCMID 414 Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the 415 safety of targeted and biological therapies: an infectious diseases perspective (Soluble 416 immune effector molecules [II]: agents targeting interleukins, immunoglobulins and 417 complement factors) Eosinophils, eosinophil ribonucleases, and their role in 419 host defense against respiratory virus pathogens Newly identified 421 respiratory viruses in children with asthma exacerbation not requiring admission to 422 hospital September epidemic of asthma exacerbations in children: a search for etiology The 427 relationship between upper respiratory infections and hospital admissions for asthma: a 428 time-trend analysis Prevalence 430 of viral respiratory tract infections in children with asthma SARS and other coronaviruses as causes of pneumonia Risk factors for severity and mortality in 435 adult COVID-19 inpatients in Wuhan Neutrophil-to-lymphocyte ratio as an 437 independent risk factor for mortality in hospitalized patients with COVID-19 Clinical characteristics of refractory 440 COVID-19 pneumonia in Wuhan, China Dysregulation of immune response in 442 patients with COVID-19 in Wuhan, China Clinical Features of 85 Fatal Cases of 444 COVID-19 from Wuhan: A Retrospective Observational Study Clinical Characteristics of 447 Coronavirus Disease 2019 in China Clinical course and risk factors for mortality 449 of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Patients of COVID-19 may benefit from 452 sustained lopinavir-combined regimen and the increase of eosinophil may predict the 453 outcome of COVID-19 progression Differentiation and 455 activation of eosinophils in the human bone marrow during experimental human 456 endotoxemia Pulmonary Pathology of Early-Phase COVID-19) Pneumonia in Two Patients With Lung Cancer Pathological findings of COVID-19 465 associated with acute respiratory distress syndrome Sex-467 associated TSLP-induced immune alterations following early-life RSV infection leads to 468 enhanced allergic disease Roadmap to developing a 470 recombinant coronavirus S protein receptor-binding domain vaccine for severe acute 471 respiratory syndrome Antibody responses to individual 473 proteins of SARS coronavirus and their neutralization activities 476 Contributions of the structural proteins of severe acute respiratory syndrome 477 coronavirus to protective immunity Severe acute 479 respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus 480 protectively immunizes mice Neutralizing antibody 482 against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective 483 for the protection of mice in the murine SARS model Immunization with 486 modified vaccinia virus Ankara-based recombinant vaccine against severe acute 487 respiratory syndrome is associated with enhanced hepatitis in ferrets 490 Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on 491 challenge with the SARS virus Protective immunity induced by the 493 inactivated SARS coronavirus vaccine Vaccine efficacy in 496 senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic 497 spike variants Primary severe acute 499 respiratory syndrome coronavirus infection limits replication but not lung inflammation 500 upon homologous rechallenge An epidemiologic study 502 of altered clinical reactivity to respiratory syncytial (RS) virus infection in children 503 previously vaccinated with an inactivated RS virus vaccine Understanding respiratory syncytial virus (RSV) 506 vaccine-enhanced disease Respiratory 508 syncytial virus disease in infants despite prior administration of antigenic inactivated 509 vaccine Respiratory Syncytial Virus Vaccine Approaches: a Current 511 Overview Prior immunization 513 with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) 514 nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV A double-517 inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete 518 protection in mice and induces increased eosinophilic proinflammatory pulmonary 519 response upon challenge 521 Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c 522 mice immunized with UV-inactivated severe acute respiratory syndrome-related 523 coronavirus vaccine Severe acute 525 respiratory syndrome-associated coronavirus vaccines formulated with delta inulin 526 adjuvants provide enhanced protection while ameliorating lung eosinophilic 527 immunopathology Receptor-binding domain of SARS-CoV 529 spike protein induces long-term protective immunity in an animal model A 219-mer CHO-expressing receptor-532 binding domain of SARS-CoV S protein induces potent immune responses and protective 533 immunity Characteristics of and Important Lessons From the Coronavirus 535 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From 536 the Chinese Center for Disease Control and Prevention